Sponsor study identifier
Secondary identifiers
interventional
34
1 country
1
Study Start
March 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2009
Actual (reported)Study Completion
August 2009
Actual (reported)The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 25, 2009
Actual (reported)February 27, 2009
Actual (reported)March 2009
Date type not reportedThis date has not been verified as actual or estimated.
June 2009
Actual (reported)August 2009
Actual (reported)October 4, 2011
Actual (reported)At Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale)
Number of participants who achieved a minimum 1-grade improvement in elbow and/or knee lesion using the Psoriasis Grading Scale for Target Lesion Score: 0 = No evidence of scaling, erythema, or elevation. 1 = Minimal; occasional scale, faint erythema, slight elevation. 2 = Mild; fine scales, light red color, slight elevation. 3 = Moderate; coarse scales, moderate red coloration and elevation . 4 = Marked; thick scale, bright red coloration, marked elevation. 5 = Severe; very thick tenacious scale predominates, dusky to deep red coloration, very marked elevation.
Baseline to day 15
At Least 1 Grade Improvement Psoriasis Grading Scale
Baseline, days 3 and 8
At Least a 2 Grade Improvement Psoriasis Grading Scale
Baseline, days 3, 8, 15
At Least a 3 Grade Improvement Psoriasis Grading Scale
Baseline, days 3, 8, 15
At Least 1 Grade Improvement in the Psoriasis Global Assessment
Baseline, days 3, 8, 15
At Least a 2 Grade Improvement in the Psoriasis Global Assessment
Baseline, days 3, 8, 15
Olux-E (clobetasol propionate 0.05%) foam
Clobex (clobetasol propionate 0.05%) lotion.
Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
Wake Forest University Health Sciences Department of Dermatology
Winston-Salem, North Carolina, 27157, United States
GSK Clinical Trials
GlaxoSmithKline
34 participants (actual enrollment reported by the registry).
First Submitted
February 25, 2009
First Posted
February 27, 2009
Study Start
March 2009
Date type not reportedThis date has not been verified as actual or estimated.
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
June 2009
Actual (reported)Study Completion
August 2009
Actual (reported)Last Updated
April 23, 2012
Results First Posted
October 4, 2011
Record last verified: 2012-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: